MRTX logo

Mirati Therapeutics (MRTX) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

15 July 2013

Indexes:

Not included

Description:

Mirati Therapeutics, Inc. is a biotechnology company engaged in clinical research of oncological diseases. It develops drugs for the treatment of genetic and immunological diseases that contribute to the development of cancer. It was founded in 1995, with headquarters located in California (USA). Currently, Mirati Therapeutics' clinical programs consist of two drugs: MRTX849, an inhibitor of KRAS G12C - the RAS gene family is the most frequently mutated oncogene, with mutations in this gene family occurring in approximately 25% of all cancer cases. Sitravatinib, a kinase inhibitor - is designed to inhibit receptor tyrosine kinases.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Feb 28, 2024

Recent annual earnings:

Feb 28, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

10 Oct '23 Piper Sandler
Neutral
09 Oct '23 Scotiabank
Sector Perform
09 Oct '23 Jefferies
Hold
09 Oct '23 JMP Securities
Market Perform
09 Oct '23 B. Riley Securities
Neutral
06 Oct '23 Stifel
Buy
06 Oct '23 JMP Securities
Market Outperform
06 Oct '23 BMO Capital
Market Perform
28 Sept '23 JMP Securities
Market Outperform
10 Aug '23 Citigroup
Buy

Screeners with MRTX included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Similar stocks

How this insider trader nailed every single stock trade
How this insider trader nailed every single stock trade
How this insider trader nailed every single stock trade
MRTX
Finbold05 April 2024

Sometimes, insider trading goes beyond just trading based on confidential information. It involves manipulating information for profit while also sharing it with others, causing significant impacts on the stock market.

Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC
Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC
Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC
MRTX
Zacks Investment Research11 January 2024

Mirati's (MRTX) Krazati gets the European Commission's conditional marketing approval for treating adult patients with KRASG12C-mutated advanced non-small cell lung cancer.

Mirati (MRTX) Up 1.1% Since Last Earnings Report: Can It Continue?
Mirati (MRTX) Up 1.1% Since Last Earnings Report: Can It Continue?
Mirati (MRTX) Up 1.1% Since Last Earnings Report: Can It Continue?
MRTX
Zacks Investment Research06 December 2023

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock?

Mirati's lung cancer drug gets EU's regulatory backing
Mirati's lung cancer drug gets EU's regulatory backing
Mirati's lung cancer drug gets EU's regulatory backing
MRTX
Reuters10 November 2023

Mirati Therapeutics said on Friday the European medicines regulator's panel has recommended approval of its treatment for a type of lung cancer.

Mirati's (MRTX) Q3 Loss Narrows, Sales Miss Expectations
Mirati's (MRTX) Q3 Loss Narrows, Sales Miss Expectations
Mirati's (MRTX) Q3 Loss Narrows, Sales Miss Expectations
MRTX
Zacks Investment Research07 November 2023

Mirati (MRTX) posts mixed third-quarter results as the bottom line exceeds estimates while the top line misses.

Analysts Target Biotech Name on Buyout Buzz
Analysts Target Biotech Name on Buyout Buzz
Analysts Target Biotech Name on Buyout Buzz
MRTX
Schaeffers Research09 October 2023

Mirati Therapeutics Inc (NASDAQ:MRTX) stock is dropping today, after news that Bristol-Myers Squibb (BMY) will acquire the company for up to $5.8 billion.

Bristol-Myers Squibb to acquire Mirati in a $4.8 billion deal
Bristol-Myers Squibb to acquire Mirati in a $4.8 billion deal
Bristol-Myers Squibb to acquire Mirati in a $4.8 billion deal
MRTX
Reuters08 October 2023

Bristol-Myers Squibb is set to acquire cancer drugmaker Mirati Therapeutics for $58 per share in cash, representing $4.8 billion equity value.

Mirati (MRTX) Surges 45% as Sanofi Reportedly Eyes Buyout
Mirati (MRTX) Surges 45% as Sanofi Reportedly Eyes Buyout
Mirati (MRTX) Surges 45% as Sanofi Reportedly Eyes Buyout
MRTX
Zacks Investment Research06 October 2023

A Bloomberg article suggests that pharma giant Sanofi (SNY) is exploring a potential acquisition deal for small cancer drugmaker Mirati Therapeutics (MRTX).

Mirati (MRTX) Soars 12.3%: Is Further Upside Left in the Stock?
Mirati (MRTX) Soars 12.3%: Is Further Upside Left in the Stock?
Mirati (MRTX) Soars 12.3%: Is Further Upside Left in the Stock?
MRTX
Zacks Investment Research22 September 2023

Mirati (MRTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Mirati (MRTX) Q2 Earnings Beat, Stock Up on Solid Krazati Sales
Mirati (MRTX) Q2 Earnings Beat, Stock Up on Solid Krazati Sales
Mirati (MRTX) Q2 Earnings Beat, Stock Up on Solid Krazati Sales
MRTX
Zacks Investment Research09 August 2023

Mirati (MRTX) reports better-than-expected second-quarter earnings while revenues miss by a slight margin. Its CEO steps down.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the primary business of Mirati Therapeutics?
  • What is the ticker symbol for Mirati Therapeutics?
  • Does Mirati Therapeutics pay dividends?
  • What sector is Mirati Therapeutics in?
  • What industry is Mirati Therapeutics in?
  • What country is Mirati Therapeutics based in?
  • When did Mirati Therapeutics go public?
  • Is Mirati Therapeutics in the S&P 500?
  • Is Mirati Therapeutics in the NASDAQ 100?
  • Is Mirati Therapeutics in the Dow Jones?
  • When was Mirati Therapeutics's last earnings report?
  • When does Mirati Therapeutics report earnings?
  • Should I buy Mirati Therapeutics stock now?

What is the primary business of Mirati Therapeutics?

Mirati Therapeutics, Inc. is a biotechnology company engaged in clinical research of oncological diseases. It develops drugs for the treatment of genetic and immunological diseases that contribute to the development of cancer. It was founded in 1995, with headquarters located in California (USA). Currently, Mirati Therapeutics' clinical programs consist of two drugs: MRTX849, an inhibitor of KRAS G12C - the RAS gene family is the most frequently mutated oncogene, with mutations in this gene family occurring in approximately 25% of all cancer cases. Sitravatinib, a kinase inhibitor - is designed to inhibit receptor tyrosine kinases.

What is the ticker symbol for Mirati Therapeutics?

The ticker symbol for Mirati Therapeutics is NASDAQ:MRTX

Does Mirati Therapeutics pay dividends?

No, Mirati Therapeutics does not pay dividends

What sector is Mirati Therapeutics in?

Mirati Therapeutics is in the Healthcare sector

What industry is Mirati Therapeutics in?

Mirati Therapeutics is in the Biotechnology industry

What country is Mirati Therapeutics based in?

Mirati Therapeutics is headquartered in United States

When did Mirati Therapeutics go public?

Mirati Therapeutics's initial public offering (IPO) was on 15 July 2013

Is Mirati Therapeutics in the S&P 500?

No, Mirati Therapeutics is not included in the S&P 500 index

Is Mirati Therapeutics in the NASDAQ 100?

No, Mirati Therapeutics is not included in the NASDAQ 100 index

Is Mirati Therapeutics in the Dow Jones?

No, Mirati Therapeutics is not included in the Dow Jones index

When was Mirati Therapeutics's last earnings report?

Mirati Therapeutics's most recent earnings report was on 28 February 2024

When does Mirati Therapeutics report earnings?

The date for Mirati Therapeutics's next earnings report has not been announced yet

Should I buy Mirati Therapeutics stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions